Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company headquartered in Waltham, Massachusetts, focused on bioprocessing technologies and systems that support the manufacturing of biological drugs. This news page aggregates company announcements, earnings updates, product launches and strategic developments directly related to Repligen’s operations in bioprocessing.
According to its public communications, Repligen serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs), with core focus areas in Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. News items often highlight how these focus areas evolve through new products, partnerships and technology integrations.
Investors and industry followers can use this page to review earnings press releases and related Form 8-K announcements, which cover quarterly financial results, guidance updates and commentary on demand trends across Repligen’s franchises and geographies. The company’s releases also discuss the use of non-GAAP financial measures and provide reconciliations to GAAP results.
Repligen’s news flow additionally includes product and technology updates, such as the launch of new chromatography resins in its proteins portfolio and introductions of equipment in areas like mixing and process analytics. Strategic partnerships, including its collaboration with Novasign to integrate machine learning and modeling workflows into Repligen filtration systems, are another recurring theme.
Governance and leadership developments, such as Board chair transitions and senior finance appointments disclosed via press releases and Form 8-K filings, also appear in the news stream. By checking this page regularly, readers can follow how Repligen describes its progress in bioprocessing technology leadership, digitalization initiatives, and its engagement with the biopharmaceutical and CDMO sectors.
Repligen (NASDAQ:RGEN) reported Q3 2025 revenue of $189M, up 22% reported and 18% organic year‑over‑year, and raised full‑year revenue guidance to $729M–$737M. The company said all franchises and geographies posted double‑digit growth, consumables and capital equipment grew >20%, and Process Analytics equipment placements hit a record quarter after the SoloVPE PLUS launch.
Q3 GAAP net income was $15M and adjusted net income was $26M; GAAP EPS was $0.26 and adjusted EPS was $0.46. Cash and cash equivalents were $749M at Sept 30, 2025. FY2025 adjusted guidance includes organic, non‑COVID growth of 14%–15.5%, adjusted operating income of $98M–$100M, and adjusted EPS of $1.65–$1.68.
Repligen (NASDAQ:RGEN) will report its third quarter 2025 financial results on Tuesday, October 28, 2025. A press release will be issued before the market opens, followed by a conference call at 8:30 a.m. ET to discuss business updates and results for the three- and nine-month periods ended September 30, 2025.
The live call is accessible toll-free at (800) 715-9871 (U.S.) or (646) 307-1963 (international) with no passcode required. A webcast will be available and archived via the company Investor Relations website, and a replay will be posted after the event.
Repligen Corporation (NASDAQ:RGEN), a bioprocessing technology leader in life sciences, has announced its participation in three major healthcare conferences in September 2025:
- Wells Fargo Healthcare Conference (Sept 3-5, Boston) - CEO Olivier Loeillot to join analyst discussion on Sept 4 at 8:00 a.m. ET
- Deutsche Bank Healthcare Summit (Sept 10-11, NYC) - CFO Jason Garland to hold 1x1 meetings on Sept 10
- Bank of America Global Healthcare Conference (Sept 23-25, London) - CEO Olivier Loeillot to participate in analyst discussion on Sept 25 at 6:35 a.m. ET
Live webcasts will be available on Repligen's Investor Relations website with limited-time replay access.
Repligen (NASDAQ:RGEN) has announced a strategic partnership with Novasign to enhance its bioprocessing digitalization capabilities. The collaboration involves integrating Novasign's machine learning and modeling workflow into Repligen's tangential flow filtration (TFF) systems.
As part of the agreement, Repligen will make an investment in Novasign to support its expansion. The partnership aims to leverage digital twins technology and AI-powered solutions to streamline process development, enable real-time predictive control, and reduce development timelines and costs in bioprocessing operations.
The integration will strengthen Repligen's Process Analytical Technology (PAT)-enabled systems and create opportunities for advanced AI modeling within Repligen platforms.
Repligen (NASDAQ:RGEN) reported strong Q2 2025 financial results with revenue reaching $182 million, marking a 15% year-over-year increase and 17% organic non-COVID growth. The company demonstrated robust performance with orders growing over 20% year-over-year, marking the eighth consecutive quarter of orders exceeding non-COVID revenue.
Key financial metrics include GAAP net income of $15 million ($0.26 per share) and adjusted net income of $21 million ($0.37 per share). The company maintains a strong balance sheet with $709 million in cash and equivalents.
Based on strong execution and visibility, Repligen increased its full-year 2025 revenue guidance to $715-$735 million, representing 12.5-15.5% year-over-year non-COVID organic growth. The company launched ProConnex® MixOne and published its 2024 Sustainability report.
Repligen Corporation (NASDAQ:RGEN) has scheduled its second quarter 2025 financial results announcement for Tuesday, July 29, 2025. The company will release its earnings before market open and host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six-month periods ended June 30, 2025.
Investors can access the conference call via phone at (800) 715-9871 (domestic) or (646) 307-1963 (international). A webcast will also be available through the company's Investor Relations website. Both the call and webcast will be archived for future access, with replay available at (800) 770-2030 (US) or (609) 800-9909 (international) using passcode 7706699.
Repligen Corporation (NASDAQ:RGEN), a leading bioprocessing technology company, has announced its participation in the William Blair 45th Annual Growth Stock Conference. The event is scheduled for June 3-5 in Chicago. Olivier Loeillot, President and CEO, will deliver a company overview presentation on June 3rd at 1:20 p.m. CT. Investors can access the live webcast through Repligen's Investor Relations website, with a replay available for a limited time after the event.
Repligen Corporation (NASDAQ:RGEN), a bioprocessing technology leader in life sciences, has announced its participation in two major investor conferences in May 2025. The company's Chief Financial Officer, Jason K. Garland, will represent Repligen at:
1. RBC Capital Markets' 2025 Global Healthcare Conference in New York (May 20-21), featuring an analyst-led discussion on May 20 at 3:35 p.m. ET
2. Craig-Hallum's 22nd Annual Institutional Investor Conference in Minneapolis (May 28)
Both events will include one-on-one meetings with investors. The RBC conference presentation will be available via live webcast on Repligen's Investor Relations website.
Repligen reported strong Q1 2025 financial results with revenue reaching $169 million, marking a 10% year-over-year increase and 14% organic non-COVID growth. The company saw orders grow nearly 20% across all franchises.
Key highlights include:
- Biopharma and consumables revenue increased over 20% year-over-year
- Completed acquisition of 908 Devices' bioprocessing portfolio
- Launched CTech™ SoloVPE® Plus System for UV-based analysis
- Adjusted operating income up 72% year-over-year
Financial metrics show improvement with GAAP gross profit at $91 million and adjusted earnings per share of $0.39. The company maintains its 2025 guidance with expected revenue of $695M-$720M and organic growth of 9.5%-13.5%. Cash position remains strong at $697 million as of March 31, 2025.